Signalling lymphocytic activation molecule-F7 (SLAMF7). Studies have shown that SLAMF7 is overexpressed on multiple myeloma cell surfaces in studies and is therefore considered a target of multiple myeloma therapy [57]. The gene discussed is SLAMF7; the disease is plasma cell myeloma.